Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kaoru Noborio-Hatano"'
Autor:
Yusuke Furukawa, Tohru Izumi, Jiro Kikuchi, Taeko Wada, R Shimizu, Miyuki Akutsu, Yasuhiko Kano, Masaharu Nobuyoshi, Keiya Ozawa, Kaoru Noborio-Hatano, Kanae Mitsunaga
Publikováno v:
Blood. 116:406-417
Bortezomib is now widely used for the treatment of multiple myeloma (MM); however, its action mechanisms are not fully understood. Despite the initial results, recent investigations have indicated that bortezomib does not inactivate nuclear factor-κ
Autor:
Yusuke Furukawa, Tomoaki Wada, Masaaki Takatoku, Masuzu Ueda, Kazuo Muroi, R Shimizu, Jiro Kikuchi, Tadashi Nagai, Yasuhiko Kano, Sato Kazuya, Kaoru Noborio-Hatano, Iekuni Oh, Tatsuya Suzuki, Masaki Mori, Katsutoshi Ozaki, Keiya Ozawa, Masaharu Nobuyoshi
Publikováno v:
Oncogene. 28:231-242
Multiple myeloma (MM) is incurable, mainly because of cell adhesion-mediated drug resistance (CAM-DR). In this study, we performed functional screening using short hairpin RNA (shRNA) to define the molecule(s) responsible for CAM-DR of MM. Using four
Autor:
Masaaki, Takatoku, Kaoru, Noborio-Hatano, Satoko, Takahashi, Satoru, Kikuchi, Masaki, Mori, Kazuo, Muroi, Norio, Komatsu, Keiya, Ozawa
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 45(2)
A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male pati